• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

吉格列汀：用于2型糖尿病的新型有前景的格列汀类药物。

Gemigliptin: Newer Promising Gliptin for Type 2 Diabetes Mellitus.

作者信息

Gutch Manish, Joshi Abhay, Kumar Sukriti, Agarwal Avinash, Pahan Rajendra Kumar, Razi Syed Mohd

机构信息

Department of Medicine, King George's Medical College, Lucknow, Uttar Pradesh, India.

Regional Medical Advisor, Sanofi India Ltd, Mumbai, Maharashtra, India.

出版信息

Indian J Endocrinol Metab. 2017 Nov-Dec;21(6):898-902. doi: 10.4103/ijem.IJEM_20_17.

DOI:10.4103/ijem.IJEM_20_17
PMID:29285456
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5729681/
Abstract

The dipeptidyl peptidase-4 (DPP-4) inhibitors have facilitated the management of type 2 diabetes mellitus (T2DM) owing to their superior efficacy and safety with low incidence of adverse effects. Gemigliptin is a new member of this family of drugs, and studies have revealed certain advantages of gemigliptin use compared to its previous congeners. Besides, this drug has also been studied for the treatment of T2DM as monotherapy, in combination with metformin or other oral antidiabetic drugs and in T2DM with moderate-to-severe renal failure. In this review, we explore the published data highlighting the pharmacology, efficacy, and safety of gemigliptin along with its recommendations for use in patients with T2DM.

摘要

二肽基肽酶-4（DPP-4）抑制剂因其卓越的疗效和安全性以及较低的不良反应发生率，为2型糖尿病（T2DM）的管理提供了便利。格列美脲是这类药物家族的新成员，研究表明，与之前的同类药物相比，使用格列美脲具有某些优势。此外，该药物还被研究用于单药治疗T2DM、与二甲双胍或其他口服抗糖尿病药物联合使用以及用于中重度肾衰竭的T2DM患者。在本综述中，我们探讨了已发表的数据，这些数据突出了格列美脲的药理学、疗效和安全性以及其在T2DM患者中的使用建议。

相似文献

1
Gemigliptin: Newer Promising Gliptin for Type 2 Diabetes Mellitus.吉格列汀：用于2型糖尿病的新型有前景的格列汀类药物。
Indian J Endocrinol Metab. 2017 Nov-Dec;21(6):898-902. doi: 10.4103/ijem.IJEM_20_17.
2
Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus.用于治疗2型糖尿病的二肽基肽酶4抑制剂的临床药理学
Clin Exp Pharmacol Physiol. 2015 Oct;42(10):999-1024. doi: 10.1111/1440-1681.12455.
3
A fixed-dose combination tablet of gemigliptin and metformin sustained release has comparable pharmacodynamic, pharmacokinetic, and tolerability profiles to separate tablets in healthy subjects.在健康受试者中，吉格列汀与二甲双胍缓释片的固定剂量复方片剂与单一片剂相比，具有相似的药效学、药代动力学和耐受性特征。
Drug Des Devel Ther. 2015 Feb 4;9:729-36. doi: 10.2147/DDDT.S75980. eCollection 2015.
4
Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus.吉格列汀：2型糖尿病管理中临床应用的最新进展
Diabetes Metab J. 2016 Oct;40(5):339-353. doi: 10.4093/dmj.2016.40.5.339. Epub 2016 Sep 12.
5
Pharmacological profiles of gemigliptin (LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo.新型二肽基肽酶-4抑制剂吉格列汀（LC15-0444）的体外和体内药理学特性
Eur J Pharmacol. 2016 Oct 5;788:54-64. doi: 10.1016/j.ejphar.2016.06.016. Epub 2016 Jun 11.
6
Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.二肽基肽酶-4的抑制作用：一种治疗2型糖尿病的新方法。
Curr Med Res Opin. 2007 Apr;23(4):919-31. doi: 10.1185/030079906x162746.
7
Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40-week extension of the GUARD randomized study.在肾功能受损的 2 型糖尿病患者中比较 gemigliptin 与 linagliptin 的疗效和安全性：GUARD 随机研究的 40 周扩展。
Diabetes Obes Metab. 2018 Feb;20(2):292-300. doi: 10.1111/dom.13059. Epub 2017 Sep 6.
8
Effects of gemigliptin, a dipeptidyl peptidase-4 inhibitor, on lipid metabolism and endotoxemia after a high-fat meal in patients with type 2 diabetes.二肽基肽酶-4抑制剂吉格列汀对2型糖尿病患者高脂餐后脂质代谢和内毒素血症的影响。
Diabetes Obes Metab. 2017 Mar;19(3):457-462. doi: 10.1111/dom.12831. Epub 2016 Dec 19.
9
Pharmacokinetic Interactions Between Gemigliptin and Metformin, and Potential Differences in the Pharmacokinetic Profile of Gemigliptin Between the Mexican and Korean Populations: A Randomized, Open-label Study in Healthy Mexican Volunteers.中效瑞格列汀与二甲双胍的药代动力学相互作用，以及中效瑞格列汀在墨西哥和韩国人群中药代动力学特征的潜在差异：一项在健康墨西哥志愿者中开展的随机、开放标签研究。
Clin Ther. 2018 Oct;40(10):1729-1740. doi: 10.1016/j.clinthera.2018.08.015. Epub 2018 Sep 22.
10
Pharmacokinetic comparison of gemigliptin 50 mg and metformin 500 mg as a fixed-dose combination and loose combination
.50毫克吉格列汀与500毫克二甲双胍固定剂量组合及松散组合的药代动力学比较
Int J Clin Pharmacol Ther. 2019 Feb;57(2):117-124. doi: 10.5414/CP203289.

引用本文的文献

1
Autophagy and mitophagy as potential therapeutic targets in diabetic heart condition: Harnessing the power of nanotheranostics.自噬和线粒体自噬作为糖尿病心脏疾病的潜在治疗靶点：利用纳米诊疗技术的力量
Asian J Pharm Sci. 2024 Jun;19(3):100927. doi: 10.1016/j.ajps.2024.100927. Epub 2024 May 19.
2
In-lab synthesized turn-off fluorescence sensor for estimation of Gemigliptin and Rosuvastatin polypill appraised by Spider diagram, AGREE and whiteness metrics.通过蜘蛛图、AGREE和白度指标评估的用于估算格美脲和瑞舒伐他汀复方制剂的实验室合成关闭型荧光传感器。
Sci Rep. 2024 Feb 5;14(1):2927. doi: 10.1038/s41598-024-53203-z.
3
GLP-1 Analogs, SGLT-2, and DPP-4 Inhibitors: A Triad of Hope for Alzheimer's Disease Therapy.胰高血糖素样肽-1类似物、钠-葡萄糖协同转运蛋白2抑制剂和二肽基肽酶-4抑制剂：阿尔茨海默病治疗的三联希望
Biomedicines. 2023 Nov 12;11(11):3035. doi: 10.3390/biomedicines11113035.
4
Opportunities and challenges of incretin-based hypoglycemic agents treating type 2 diabetes mellitus from the perspective of physiological disposition.从生理处置角度看肠促胰岛素类降糖药物治疗2型糖尿病的机遇与挑战
Acta Pharm Sin B. 2023 Jun;13(6):2383-2402. doi: 10.1016/j.apsb.2022.11.008. Epub 2022 Nov 11.
5
Effect of Dipeptidyl Peptidase-4 (DPP-4) Inhibition on Biomarkers of Kidney Injury and Vascular Calcification in Diabetic Kidney Disease: A Randomized Controlled Trial.二肽基肽酶-4（DPP-4）抑制剂对糖尿病肾病患者肾脏损伤和血管钙化生物标志物的影响：一项随机对照试验。
J Diabetes Res. 2021 Oct 16;2021:7382620. doi: 10.1155/2021/7382620. eCollection 2021.
6
Efficacy and Safety of the Novel Dipeptidyl Peptidase-4 Inhibitor Gemigliptin in the Management of Type 2 Diabetes: A Meta-Analysis.新型二肽基肽酶-4 抑制剂吉马立肽治疗 2 型糖尿病的疗效和安全性：一项荟萃分析。
Endocrinol Metab (Seoul). 2021 Apr;36(2):374-387. doi: 10.3803/EnM.2020.818. Epub 2021 Apr 6.
7
Current Pharmacological Intervention and Medical Management for Diabetic Kidney Transplant Recipients.糖尿病肾移植受者的当前药物干预与医疗管理
Pharmaceutics. 2021 Mar 19;13(3):413. doi: 10.3390/pharmaceutics13030413.
8
Exploring the recent molecular targets for diabetes and associated complications.探讨糖尿病及其相关并发症的近期分子靶点。
Mol Biol Rep. 2021 Mar;48(3):2863-2879. doi: 10.1007/s11033-021-06294-0. Epub 2021 Mar 24.
9
Pharmacology of dipeptidyl peptidase-4 inhibitors and its use in the management of metabolic syndrome: a comprehensive review on drug repositioning.二肽基肽酶-4 抑制剂的药理学及其在代谢综合征治疗中的应用：药物重定位的综合评价。
Daru. 2019 Jun;27(1):341-360. doi: 10.1007/s40199-019-00238-7. Epub 2019 Jan 23.
10
Potentiation of endothelium-dependent vasorelaxation of mesenteric arteries from spontaneously hypertensive rats by gemigliptin, a dipeptidyl peptidase-4 inhibitor class of anti-diabetic drug.二肽基肽酶-4抑制剂类抗糖尿病药物吉格列汀增强自发性高血压大鼠肠系膜动脉内皮依赖性血管舒张作用
Korean J Physiol Pharmacol. 2018 Nov;22(6):713-719. doi: 10.4196/kjpp.2018.22.6.713. Epub 2018 Oct 25.

本文引用的文献

1
Effect of gemigliptin on glycaemic variability in patients with type 2 diabetes (STABLE study).二甲双胍格列净对 2 型糖尿病患者血糖变异性的影响（STABLE 研究）。
Diabetes Obes Metab. 2017 Jun;19(6):892-896. doi: 10.1111/dom.12869. Epub 2017 Mar 16.
2
Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, placebo-controlled study (TROICA study).二肽基肽酶-4抑制剂吉格列汀在二甲双胍和磺脲类药物联合治疗血糖控制不佳的2型糖尿病患者中的疗效和安全性：一项为期24周的多中心、随机、双盲、安慰剂对照研究（TROICA研究）
Diabetes Obes Metab. 2017 May;19(5):635-643. doi: 10.1111/dom.12866. Epub 2017 Feb 17.
3
Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus.吉格列汀：2型糖尿病管理中临床应用的最新进展
Diabetes Metab J. 2016 Oct;40(5):339-353. doi: 10.4093/dmj.2016.40.5.339. Epub 2016 Sep 12.
4
Pharmacological profiles of gemigliptin (LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo.新型二肽基肽酶-4抑制剂吉格列汀（LC15-0444）的体外和体内药理学特性
Eur J Pharmacol. 2016 Oct 5;788:54-64. doi: 10.1016/j.ejphar.2016.06.016. Epub 2016 Jun 11.
5
The Dose-Dependent Organ-Specific Effects of a Dipeptidyl Peptidase-4 Inhibitor on Cardiovascular Complications in a Model of Type 2 Diabetes.二肽基肽酶-4抑制剂对2型糖尿病模型心血管并发症的剂量依赖性器官特异性作用
PLoS One. 2016 Mar 9;11(3):e0150745. doi: 10.1371/journal.pone.0150745. eCollection 2016.
6
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY.美国临床内分泌医师协会和美国内分泌学会关于2型糖尿病综合管理算法的共识声明——2016年执行摘要
Endocr Pract. 2016 Jan;22(1):84-113. doi: 10.4158/EP151126.CS.
7
Dipeptidyl peptidase-4 inhibition by gemigliptin prevents abnormal vascular remodeling via NF-E2-related factor 2 activation.吉格列汀抑制二肽基肽酶-4可通过激活NF-E2相关因子2预防异常血管重塑。
Vascul Pharmacol. 2015 Oct;73:11-9. doi: 10.1016/j.vph.2015.07.005. Epub 2015 Jul 15.
8
Evaluation of the pharmacokinetics of the DPP-4 inhibitor gemigliptin when coadministered with rosuvastatin or irbesartan to healthy subjects.评估DPP-4抑制剂吉格列汀与瑞舒伐他汀或厄贝沙坦联合应用于健康受试者时的药代动力学。
Curr Med Res Opin. 2015 Feb;31(2):229-41. doi: 10.1185/03007995.2014.980886. Epub 2014 Nov 6.
9
Pleiotropic mechanisms for the glucose-lowering action of DPP-4 inhibitors.二肽基肽酶-4 抑制剂降低血糖作用的多效机制。
Diabetes. 2014 Jul;63(7):2196-202. doi: 10.2337/db14-0052.
10
Evaluation of pharmacokinetic drug interactions between gemigliptin (dipeptidylpeptidase-4 inhibitor) and glimepiride (sulfonylurea) in healthy volunteers.健康志愿者中吉格列汀（二肽基肽酶-4抑制剂）与格列美脲（磺脲类药物）之间药代动力学药物相互作用的评估。
Drugs R D. 2014 Sep;14(3):165-76. doi: 10.1007/s40268-014-0054-8.